2. Search Result
Search Result
Results for "

scopolamine

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

11

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0340
    Scopolamine butylbromide
    1 Publications Verification

    Hyoscine butylbromide; (-)-scopolamine butylbromide; Butylscopolamine bromide

    		 mAChR Neurological Disease
    Scopolamine butylbromide is a competitive antagonist of muscarinic acetylcholine receptor (mAChR) with an IC50 of 55.3 ± 4.3 nM.
    Scopolamine butylbromide
  • HY-W010892
    Scopolamine hydrobromide trihydrate
    Maximum Cited Publications
    11 Publications Verification

    Hyoscine hydrobromide trihydrate

    		 mAChR Neurological Disease
    Scopolamine hydrobromide trihydrate (Hyoscine hydrobromide trihydrate) is used in ophthalmic preparations and has the potential for transdermal patches of motion sickness .
    Scopolamine hydrobromide trihydrate
  • HY-W127702
    Scopolamine nitrate

    Methscopolamine nitrate

    		 Biochemical Assay Reagents Others
    Scopolamine (nitrate) is an organic compound commonly used in neuroscience research and pharmacology research. It can be used to study the role and structure of acetylcholine receptors, and is widely used in drug development and research in related fields. In addition, this compound is also used as a substrate or catalyst in certain biochemical reactions.
    Scopolamine nitrate
  • HY-B0344
    Methscopolamine bromide
    1 Publications Verification

    (-)-scopolamine methyl bromide; Hyoscine methyl bromide

    		 Biochemical Assay Reagents mAChR Others
    Methscopolamine Bromide is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Methscopolamine bromide
  • HY-120408
    (-)-Scopolamine

    Atroscine

    		 Adrenergic Receptor Neurological Disease
    (-)-Scopolamine (Atroscine) is the racemic modification of Scopolamine. (-)-Scopolamine inhibits α-adrenergic receptor activity. (-)-Scopolamine has Ki values of 33 μM and 7.25 nM for α1-adrenerg receptor and muscarinic cholinergic receptor, respectively .
    (-)-Scopolamine
  • HY-B2065
    Scopolamine hydrochloride

    (-)-scopolamine hydrochloride; Hyoscine hydrochloride

    		 mAChR 5-HT Receptor Neurological Disease
    Scopolamine hydrochloride is a non-selective and high affinity (≤1 nM) muscarinic antagonist that is used for the prevention of post-operative nausea and vomiting. Scopolamine readily passes the blood brain barrier. Scopolamine also reversibly inhibits 5-HT3 receptor-responses with an IC50 of 2.09 μM . Scopolamine induces Alzheimer's disease-like pathology through alteration of cholinergic system .
    Scopolamine hydrochloride
  • HY-168301
    CL-13

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    CL-13 is a butyrylcholinesterase (BChE) inhibitor, with an IC50 of 1.15 μM, and a selectivity index (SI) of 9.2 for acetylcholinesterase. CL-13 shows antioxidant activity in SH-SY5Y cells (DPPH EC50 = 47.01 μM) and has the ability to chelate metals involved in Aβ aggregation and/or oxidative stress, showing no neurotoxicity at 50 μM. CL-13 can reverse cognitive impairment caused by scopolamine (HY-N0296) without affecting the mice's motor skills .
    CL-13
  • HY-146677
    5-HT6R/MAO-B modulator 1

    		5-HT Receptor Monoamine Oxidase Neurological Disease
    5-HT6R/MAO-B modulator 1 (compound 48) is an antagonist of 5-HT6R at Gs signaling and an irreversible MAO-B inhibitor. 5-HT6R/MAO-B modulator 1 exhibits glioprotective properties. 5-HT6R/MAO-B modulator 1 can reverse Scopolamine-induced memory deficits . 5-HT6R/MAO-B modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    5-HT6R/MAO-B modulator 1
  • HY-P3355
    p-fin4

    		iGluR Neurological Disease
    p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
    p-fin4
  • HY-155330
    PZ-1922

    		5-HT Receptor Monoamine Oxidase Neurological Disease
    PZ-1922 (Compound 16) is a BBB-penetrable 5-HT6R/5-HT3R antagonist (Ki: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 reversibly inhibits MAO-B (pIC50: 8.93). PZ-1922 reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 prevents Aβ-induced memory decline in the T-maze test .
    PZ-1922
  • HY-155330A
    PZ-1922 free base

    		5-HT Receptor Monoamine Oxidase Neurological Disease
    PZ-1922 free base is a BBB-penetrable 5-HT6R/5-HT3R antagonist (Ki: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 free base reversibly inhibits MAO-B (pIC50: 8.93). PZ-1922 free base reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 free base prevents Aβ-induced memory decline in the T-maze test .
    PZ-1922 free base
  • HY-P3354
    p3Ysh-3

    		iGluR Neurological Disease
    p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .
    p3Ysh-3
  • HY-149340
    PD07

    		Cholinesterase (ChE) Neurological Disease
    PD07 is an orally active AChE inhibitor (IC50: 0.29 μM for hAChE). PD07 also inhibits ChEs, BACE1 (IC50: 13.42 μM), and Aβ1–42 aggregation in in vitro. PD07 is an antioxidant, and shows DPPH inhibitory activity (IC50: 26.46 μM). PD07 improves memory and cognition in Scopolamine (HY-N0296)-induced amnesia rats. PD07 can be used for research of Alzheimer’s disease .
    PD07
  • HY-N11872
    Suffruticosol A

    		Others Neurological Disease
    Suffruticosol A is a neuroprotective agent that restores scopolamine-induced cellular neurodegenerative damage. Suffruticosol A ameliorates hippocampal cholinergic deficits and partially enhances BDNF signaling. Suffruticosol A has neuromodulatory effects in a Scopolamine (HY-N0296)-induced model, restoring memory and cognitive performance in mice. Suffruticosol A can be isolated from seeds of P. lactiflora .
    Suffruticosol A
  • HY-N7061
    Tropine

    		Others Neurological Disease
    Tropine is a secondary metabolite of Solanaceae plants, is an anticholinergic agent . Tropine is a common intermediate in the synthesis of a variety of bioactive alkaloids, including hyoscyamine and scopolamine .
    Tropine
  • HY-105435
    FR121196

    		Others Neurological Disease
    FR121196 is a cognitive enhancer, and ameliorates Scopolamine (HY-N0296)-induced memory deficit. FR121196 is an antidementia compound .
    FR121196
  • HY-N0541
    Pseudoginsenoside F11
    1 Publications Verification

    Ginsenoside A1

    		 Endogenous Metabolite Others
    Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.
    Pseudoginsenoside F11
  • HY-N7061R
    Tropine (Standard)

    		Others Neurological Disease
    Tropine (Standard) is the analytical standard of Tropine. This product is intended for research and analytical applications. Tropine is a secondary metabolite of Solanaceae plants, is an anticholinergic agent . Tropine is a common intermediate in the synthesis of a variety of bioactive alkaloids, including hyoscyamine and scopolamine .
    Tropine (Standard)
  • HY-149212
    SD-6

    		Cholinesterase (ChE) Neurological Disease
    SD-6 is an orally active inhibitor of hAChE and hBChE with IC50 values of 0.907 µM and 1.579 µM, respectively. SD-6 has excellent blood-brain barrier (BBB) permeability and no neurotoxicity, which can be used for research on Alzheimer's disease .
    SD-6
  • HY-127165
    Velnacrine

    HP 029 free base; Hydroxytacrine

    		 Cholinesterase (ChE) Neurological Disease
    Velnacrine (HP 029 free base) is an inhibitor for acetylcholinesterase (AChE), with an IC50 of 3.27 μM. Velnacrine reverses the Scopolamine (HY-N0296)-induced amnesia in rat models, and exhibits acute toxicity with LD50 of 65 mg/kg .
    Velnacrine
  • HY-157326
    hMAO-B-IN-6

    		Monoamine Oxidase Neurological Disease
    hMAO-B-IN-6 (compound 17d) is a potent and selective inhibitor of hMAO-B with an IC50 of 67.02 nM. hMAO-B-IN-6 significantly improves Scopolamine (HY-N0296)-induced cognitive impairment in AD mice .
    hMAO-B-IN-6
  • HY-P10435
    KEMPFPKYPVEP

    		Dopamine Receptor Neurological Disease
    KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model .
    KEMPFPKYPVEP
  • HY-163320
    AChE/Aβ-IN-5

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .
    AChE/Aβ-IN-5
  • HY-N4268
    Tenuifoliside B

    		Others Neurological Disease
    Tenuifoliside B, a component isolated from Polygalae Radix, inhibits potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment. Tenuifoliside B shows potential cognitive improvement and cerebral protective effects. Tenuifoliside B has potential to become an anti-AD lead compound .
    Tenuifoliside B
  • HY-116881
    SCH 57790

    		mAChR Neurological Disease
    SCH 57790 is a selective antegonist for muscarinic M2 receptor, which increases acetylcholine release, and thus improves cognitive performance. SCH 57790 reverses Scopolamine (HY-N0296)-induced memory deficits in mice, without significant toxicity (100 mg/kg).
    SCH 57790
  • HY-163646
    (Rac)-TZ3O

    		Cholinesterase (ChE) Neurological Disease
    (Rac)-TZ3O is the (Rac) isomer of TZ3O. TZ3O is an anticholinergic compound with neuroprotective activity. TZ3O improves memory impairment and cognitive decline in a scopolamine-induced Alzheimer's disease rat model and can be used in the study of Alzheimer's disease.
    (Rac)-TZ3O
  • HY-105294
    FR 64822

    		Dopamine Receptor Others
    FR 64822 is a dopamine D2 receptor agonist that can induce antinociceptive activity in rats and mice by indirectly stimulating dopamine D2 receptors. FR 64822 can promote penile erection in juvenile rats and improve amnesia in rats induced by scopolamine during passive avoidance tasks .
    FR 64822
  • HY-107652
    AF-DX 384

    		mAChR Neurological Disease
    AF-DX 384 is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively) . AF-DX 384 reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine .
    AF-DX 384
  • HY-169116
    D5R agonist 1

    		Dopamine Receptor Neurological Disease
    D5R agonist 1 (Compound 5j) is a selective, orally active and BBB penetrable D5R partial agonist (EC50: 269.7 nM). D5R agonist 1 enhances the cognition in the Scopolamine (HY-N0296)-induced amnesia model .
    D5R agonist 1
  • HY-123904
    UoS12258

    		iGluR Neurological Disease
    UoS12258 is a selective positive allosteric modulator of AMPA receptor. UoS12258 enhances AMPA receptor‐mediated synaptic transmission. UoS12258 improves performance in cognition rat models, including Scopolamine (HY-N0296)‐impaired rats and water maze learning and retention in aged rats .
    UoS12258
  • HY-149776
    RGH-560

    		nAChR Neurological Disease
    RGH-560 (compound 53) shows highly advanced α7 nAChR positive modulator properties and favorable physicochemical features. RGH-560 has robust procognitive in vivo potential. RGH-560 can be used to study Scopolamine (HY-N0296) -induced amnesia in mice .
    RGH-560
  • HY-124223
    AF-DX 384 methanesulfonate

    		mAChR Neurological Disease
    AF-DX 384 (methanesulfonate) is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively) . AF-DX 384 (methanesulfonate) reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine .
    AF-DX 384 methanesulfonate
  • HY-162339
    BChE-IN-30

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-30 (compound (R)-37a) is a BChE inhibitor (IC50: 5 nM) with anti-inflammatory activity and low toxicity. BChE-IN-30 can improve cognitive deficits induced by scopolamine and Aβ1-42 peptide and can be used in the study of late-stage AD .
    BChE-IN-30
  • HY-15112
    JTP-4819

    		Prolyl Endopeptidase (PREP) Infection
    JTP-4819 is a potent and specific inhibitor of prolyl endopeptidase (PREP) with IC50s of 0.83 nM (in rat brain supernatant) and 5.43 nM (in Flavobacterium meningosepticum). JTP-4819 has blood-brain penetration, also improves the retention time of amnesia rats induced by Scopolamine (HY-N2096) .
    JTP-4819
  • HY-155823
    TZ4M

    		Cholinesterase (ChE) Neurological Disease
    TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model .
    TZ4M
  • HY-155822
    TZ3O

    		Cholinesterase (ChE) Neurological Disease
    TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects. TZ3O (2 mg/kg, 4 mg/kg) can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research .
    TZ3O
  • HY-157384
    BChE-IN-22

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-22 (compound 5A) is a selective eqBChE inhibitor (IC50: 0.53 μM), has anti-inflammatory and neuroprotective activities. BChE-IN-22 can inhibit cell damage caused by Aβ25-35 (HY-P0128) and improve cognitive dysfunction caused by Scopolamine (HY-N0296) .
    BChE-IN-22
  • HY-146086
    Nrf2 activator-4

    		Keap1-Nrf2 Reactive Oxygen Species Neurological Disease Inflammation/Immunology
    Nrf2 activator-4 (Compound 20a) is a highly potent, orally active Nrf2 activator with an EC50 of 0.63 µM. Nrf2 activator-4 suppresses reactive oxygen species against oxidative stress in microglia. Nrf2 activator-4 effectively recovers the learning and memory impairment in a scopolamine-induced mouse model .
    Nrf2 activator-4
  • HY-10932R
    Aniracetam (Standard)

    		nAChR iGluR Neurological Disease
    Aniracetam (Standard) is the analytical standard of Aniracetam. This product is intended for research and analytical applications. Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders .
    Aniracetam (Standard)
  • HY-10932
    Aniracetam

    Ro 13-5057

    		 nAChR iGluR Neurological Disease
    Aniracetam (Ro 13-5057) is an orally active neuroprotective agent, possessing nootropics effects. Aniracetam potentiates the ionotropic quisqualate (iQA) responses in the CA1 region of rat hippocampal slices. Aniracetam also potentiates the excitatory post synaptic potentials (EPSPs) in Schaffer collateral-commissural synapses. Aniracetam can prevents the CO2-induced impairment of acquisition in hypercapnia model rats. Aniracetam can be used to research cerebral dysfunctional disorders .
    Aniracetam
  • HY-122080
    Memoquin

    		Cholinesterase (ChE) Beta-secretase Amyloid-β Neurological Disease
    Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC50 values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD) .
    Memoquin
  • HY-118642
    D-Ribose-L-cysteine

    		Cholinesterase (ChE) Reactive Oxygen Species Cardiovascular Disease Neurological Disease
    D-Ribose-L-cysteine ​​is an orally active cysteine ​​analog. D-Ribose-L-cysteine ​​improves cellular antioxidant capacity by enhancing intracellular glutathione (GSH) biosynthesis. In addition, D-Ribose-L-cysteine ​​has a memory-enhancing effect and can reverse Scopolamine (HY-N0296)-induced memory impairment by inhibiting oxidative stress and acetylcholinesterase (AChE) activity. D-Ribose-L-cysteine ​​can be used in the study of neurodegenerative and cardiovascular diseases .
    D-Ribose-L-cysteine
  • HY-118575
    DR-4004

    		5-HT Receptor Neurological Disease
    DR-4004 is a 5-HT7 receptor antagonist that attenuates the decreased level of performance produced by mCPP and the performance levels after p-chloroamphetamine (PCA) lesion of the 5-HT system. DR-4004 also reverses amnesia induced by Scopolamine (HY-N0296) and Dizocilpine (HY-15084B). DR-4004 is promising for research of schizophrenia, cognitive deficits and atypical antipsychotic agents .
    DR-4004
  • HY-118342
    PQCA

    		mAChR Neurological Disease
    PQCA is a highly selective and potent muscarinic M1 receptor positive allosteric modulator. PQCA has an EC50 value of 49 nM and 135 nM on rhesus and human M1 receptor, respectively. PQCA is inactive for other muscarinic receptors. PQCA has potential to reduce the cognitive deficits associated with Alzheimer's disease .
    PQCA
  • HY-101196
    PG 9 maleate

    		Others Neurological Disease
    PG 9 maleate is a compound with analgesic and anti-memory loss activity. PG 9 maleate exerts analgesic effects by enhancing central cholinergic transmission. PG 9 maleate protects against memory loss caused by scopolamine or dicyclomine within a specific dose range. The affinity profile of PG 9 maleate indicates significant selectivity among the M4/M1 receptor subtypes, which may be the mechanism for its analgesic and anti-memory loss effects. PG 9 maleate can increase the release of acetylcholine, thereby improving its biological activity .
    PG 9 maleate
  • HY-103142
    AS19

    		5-HT Receptor Neurological Disease
    AS19 is a potent, selective 5-HT7 receptor agonist with an IC50 value of 0.83 nM and a Ki of 0.6 nM. AS19 is selective for 5-HT7 over 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT5A receptors (Kis = 89.7 nM, 490 nM, 6.6 nM and 98.5 nM, respectively). AS19 enhances memory consolidation and reverses Scopolamine- or Dizocilpine-induced amnesia .
    AS19
  • HY-N1441
    Afzelin
    4 Publications Verification

    Kaempferol-3-O-rhamnoside

    		 Mitochondrial Metabolism PTEN Autophagy Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin .
    Afzelin
  • HY-159898
    AChE/BChE-IN-23

    		Cholinesterase (ChE) Amyloid-β Tau Protein NOD-like Receptor (NLR) Reactive Oxygen Species Mitochondrial Metabolism Neurological Disease
    AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model .
    AChE/BChE-IN-23
  • HY-N1441R
    Afzelin (Standard)

    		Mitochondrial Metabolism PTEN Autophagy Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Afzelin (Standard) is the analytical standard of Afzelin. This product is intended for research and analytical applications. Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin .
    Afzelin (Standard)
  • HY-158978
    Multitarget AD inhibitor-2

    		Cholinesterase (ChE) Monoamine Oxidase Neurological Disease
    Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC50=0.14 μM), butyrylcholinesterase (BChE, IC50=11.6 μM), monoamine oxidase B (MAO B, IC50=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .
    Multitarget AD inhibitor-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: